Takeda and Chembio Diagnostics Collaborate to Develop Point-of-Care Diagnostic Test

 Takeda and Chembio Diagnostics Collaborate to Develop Point-of-Care Diagnostic Test

Takeda and Chembio Diagnostics Collaborate to Develop Point-of-Care Diagnostic Test

Shots:

  • Chembio to receive funding if reaches certain milestones, to develop POC test utilizing Chembio’s DPP platform and hand-held optical analyzer. The POC test will be built upon Takeda’s biomarker and is expected to provide results in ~15 mins. from a 10µL drop of fingerstick blood
  • The collaboration is to combine Chembio’s DPP platform and Takeda’s expertise to develop and commercialize a novel POC diagnostic test to improve patient’s health
  • Chembio’s DPP technology utilizes a small drop of blood from the fingertip to detect diseases and is also used for DPP HIV 1/2 Assay which has received the US FDA and ANVISA’s approval, CLIA-waiver, WHO prequalification and CE mark

Click here to read full press release/ article | Ref: Globe NewsWire | Image: Takeda

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post